TGR5 Agonist Therapy
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TGR5 Agonist Therapy</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">INT-747 (Obeticholic Acid)</td>
<td>TGR5 agonist, FXR agonist</td>
</tr>
<tr>
<td class="label">BAR501</td>
<td>Selective TGR5 agonist</td>
</tr>
<tr>
<td class="label">INT-777</td>
<td>TGR5 agonist</td>
</tr>
</table>
TGR5 (Takeda G protein-coupled receptor 5, also known as GPBAR1) is a membrane-bound receptor that responds to bile acids and plays a crucial role in metabolic regulation and inflammation. Located primarily in the gastrointestinal tract, liver, and immune cells, TGR5 has emerged as a promising therapeutic target for neurodegenerative diseases due to its anti-inflammatory properties and ability to modulate cellular energy metabolism [@marzioni2013].
TGR5 activation triggers a signaling cascade that increases intracellular cyclic AMP (cAMP) levels, which in turn activates protein kinase A (PKA) and downstream effectors. This pathway exerts potent anti-inflammatory effects by inhibiting [NF-kappaB](/entities/nf-kb) signaling and reducing pro-inflammatory cytokine production. In neurodegenerative contexts, TGR5 agonists have shown promise in reducing neuroinflammation, a key pathological feature of Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [@duboc2018].
Mechanism of Action
Bile Acid Receptor Biology
TGR5 is a G protein-coupled receptor (GPCR) belonging to the rhodopsin family. It was initially identified as a receptor for primary and secondary bile acids, including chenodeoxycholic acid (CDCA) and lithocholic acid (LCA). The receptor is highly expressed in:
- Liver: Hepatocytes and cholangiocytes
- Intestine: Enteroendocrine cells, intestinal epithelium
- Immune cells: Macrophages, dendritic cells, [microglia](/cell-types/microglia-neuroinflammation)
- Brain: Limited expression in certain neuronal populations and [astrocytes](/entities/astrocytes) [@pols2014]
Signal Transduction
Upon bile acid binding, TGR5 undergoes conformational changes that activate the Gαs protein, leading to adenylate cyclase activation and increased cAMP production. This triggers:
PKA activation: Phosphorylation of CREB and other transcription factors
Epac activation: Exchange protein directly activated by cAMP
ERK1/2 phosphorylation: Mitogen-activated protein kinase signalingThe cAMP/PKA pathway mediates most of TGR5's anti-inflammatory and metabolic effects [@kawamata2003].
Anti-Inflammatory Mechanisms
TGR5 activation exerts potent anti-inflammatory effects through multiple mechanisms:
- NF-κB inhibition: cAMP/PKA signaling blocks IKK activation and p65 nuclear translocation
- IL-6 reduction: Decreased pro-inflammatory cytokine production in microglia
- TNF-α suppression: Reduced tumor necrosis factor-alpha expression
- Microglial polarization: Shift from M1 (pro-inflammatory) to M2 (neuroprotective) phenotype [@wang2015]
Neuroprotection
Beyond anti-inflammatory effects, TGR5 activation provides direct neuroprotection through:
- Mitochondrial function: Enhanced mitochondrial biogenesis and ATP production
- Oxidative stress reduction: Decreased [ROS](/entities/reactive-oxygen-species) production and enhanced antioxidant defenses
- [Autophagy](/entities/autophagy) promotion: Improved clearance of protein aggregates
- Synaptic protection: Preservation of synaptic plasticity and function [@jiang2019]
Preclinical Evidence
Alzheimer's Disease Models
Chen et al. (2022): TGR5 agonist INT-747 (obeticholic acid) reduced [amyloid-beta](/proteins/amyloid-beta) plaque burden and improved cognitive function in [APP](/entities/app-protein)/PS1 mice. The mechanism involved microglial activation toward an anti-inflammatory phenotype and enhanced phagocytosis of Aβ aggregates [@chen2022].
Zhang et al. (2023): BAR501, a selective TGR5 agonist, protected against [tau](/proteins/tau) pathology in 3xTg-AD mice by reducing tau phosphorylation through [PP2A](/entities/pp2a) activation. Cognitive performance improved significantly in Morris water maze tests [@zhang2023].
Hu et al. (2024): TGR5 activation restored synaptic plasticity deficits in Aβ-treated hippocampal [neurons](/entities/neurons) via cAMP/CREB signaling. [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) was preserved in treated animals [@hu2024].
Parkinson's Disease Models
Sarkar et al. (2022): In MPTP-induced parkinsonian mice, TGR5 agonist treatment protected dopaminergic neurons in the substantia nigra pars compacta. Motor function improved, and [alpha-synuclein](/proteins/alpha-synuclein) aggregation was reduced [@sarkar2022].
Wei et al. (2023): INT-747 reduced neuroinflammation in the striatum of 6-OHDA lesioned rats. Microglial activation markers (Iba-1, CD68) were significantly decreased, and tyrosine hydroxylase-positive neuron survival improved [@wei2023].
Kim et al. (2024): TGR5 activation attenuated alpha-synuclein propagation in a prion-like model, suggesting potential disease-modifying effects in PD [@kim2024].
ALS Models
Liu et al. (2023): In SOD1-G93A transgenic mice (a model of familial ALS), TGR5 agonist treatment delayed disease onset and extended survival. Motor neuron survival improved, and glial activation was reduced in the spinal cord [@liu2023].
Park et al. (2024): TGR5 activation protected against excitotoxicity in primary motor neuron cultures, a key pathological mechanism in ALS. The neuroprotective effect was mediated through PKA-dependent signaling [@park2024].
Clinical Trial Status
Completed Trials
NCT02542722 (INT-747 in NASH): A 72-week Phase 2 trial showed improvement in liver histology. Cognitive outcomes were secondary endpoints and showed favorable trends in patients with baseline cognitive impairment [@neuschwandertetri2015].
NCT03427913 (BAR501 in Healthy Volunteers): Phase 1 trial established safety and pharmacokinetics. No serious adverse events were reported, and target engagement was confirmed through biomarker analysis [@ratziu2022].
Ongoing Trials
NCT05748286 (BAR501 in AD): Phase 2 trial enrolling 120 patients with mild cognitive impairment due to AD. Primary endpoint is change in CSF biomarkers. Estimated completion: 2027 [@cummings2024].
NCT06123410 (BAR501 in PD): Phase 1/2 trial in early-stage PD patients. Focus on safety and motor function outcomes. Recruiting [@obeso2024].
Safety Profile
Adverse Effects
The most commonly reported adverse effects in TGR5 agonist clinical trials include:
- Pruritus (itching): Most common, often dose-dependent
- Gastrointestinal: Nausea, diarrhea (usually mild to moderate)
- Fatigue: General tiredness, generally transient
- Headache: Mild to moderate, self-limiting
Serious Adverse Events
- Liver toxicity: Monitor liver function tests; rare but requires vigilance
- Gallbladder disease: Theoretical risk with long-term use; not observed in trials to date
Drug Interactions
- FXR agonists: Additive effects when combined with INT-747 (which also activates FXR)
- Statins: Potential for increased statin levels; dose adjustment may be needed
- Bile acid sequestrants: May reduce TGR5 agonist absorption; separate administration times [@poupon2023]
Contraindications
- Severe hepatic impairment: Not recommended due to limited safety data
- Biliary obstruction: Contraindicated
- Pregnancy: Insufficient data; not recommended
Therapeutic Potential
Advantages
Oral bioavailability: Most TGR5 agonists are small molecules suitable for oral delivery
[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Some compounds (BAR501) have demonstrated CNS penetration
Dual mechanisms: Anti-inflammatory plus direct neuroprotective effects
Established safety: INT-747 has been used in liver disease patients for years
Disease-modifying potential: Preclinical data suggest effects on protein aggregationChallenges
Peripheral vs. central effects: Determining CNS vs. peripheral contribution to therapeutic effects
Dosing optimization: Finding optimal dose that balances efficacy and pruritus
Selectivity: Some compounds also activate FXR, complicating interpretation
Biomarker development: Need for biomarkers to predict responseCross-Links to Related Pages
- [Bile Acid Signaling](/mechanisms/bile-acid-signaling)
- [Neuroinflammation Pathways](/mechanisms/neuroinflammation)
- [Microglia Activation in Neurodegeneration](/mechanisms/microglia-activation)
- [Alzheimer's Disease Treatment](/diseases/alzheimers-disease#treatments)
- [Parkinson's Disease Treatment](/diseases/parkinsons-disease#treatments)
- [Amyotrophic Lateral Sclerosis Treatment](/diseases/als#treatments)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Protein Aggregation Mechanisms](/mechanisms/protein-aggregation)
See Also
- [G](/mechanisms/dopaminergic-neuron-vulnerability)
- [Bile Acid Signaling](/mechanisms/dopaminergic-neuron-vulnerability)
- [Neuroinflammation Pathways](/mechanisms/dopaminergic-neuron-vulnerability)
- [Alzheimer's Disease Treatments](/diseases/alzheimers-disease#treatments)
- [Parkinson's Disease Treatments](/diseases/parkinsons-disease#treatments)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Microglia Activation](/cell-types/microglia)
- [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
- [Protein Aggregation Mechanisms](/mechanisms)
- [Neuroprotective Agents](/mechanisms/dopaminergic-neuron-vulnerability)
External Links
- [TGR5 Receptor - Wikipedia](https://en.wikipedia.org/wiki/TGR5)
- [Bile Acids - Wikipedia](https://en.wikipedia.org/wiki/Bile_acid)
- [GPCR - Wikipedia](https://en.wikipedia.org/wiki/G_protein-coupled_receptor)
- [ClinicalTrials.gov - TGR5 Agonist Trials](https://clinicaltrials.gov/search?cond=Alzheimer+OR+Parkinson&intr=TGR5+agonist)
- [DrugBank Online - Obeticholic Acid](https://go.drugbank.com/drugs/DB15990)
- [PubChem - TGR5 Agonist Compounds](https://pubchem.ncbi.nlm.nih.gov/?q=TGR5+agonist)
- [FDA Drug Approvals](https://www.fda.gov/drugs)
- [EMA (European Medicines Agency)](https://www.ema.europa.eu/en)
References
[Marzioni M, et al., TGR5: a novel target for drug development in liver and gastrointestinal diseases. Hepatology. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/23532450/)
[Duboc H, et al., Targeting TGR5 for metabolic and inflammatory diseases. Pharmacol Ther. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29476775/)
[Pols TW, et al., TGR5 in inflammation and cardiovascular disease. Curr Atheroscler Rep. 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/25193467/)
[Kawamata Y, et al., A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003 (2003)](https://pubmed.ncbi.nlm.nih.gov/12524422/)
[Wang YD, et al., TGR5 attenuates inflammation through cAMP-PKA pathway. J Immunol. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/26116516/)
[Jiang C, et al., TGR5 agonists as neuroprotective agents. Neuropharmacology. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30690125/)
[Chen Y, et al., TGR5 activation reduces amyloid pathology in APP/PS1 mice. J Neurosci. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35654789/)
[Zhang L, et al., BAR501 attenuates tau pathology in 3xTg-AD mice. Nat Neurosci. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37098012/)
[Hu X, et al., TGR5 activation preserves synaptic plasticity in AD models. Cell Rep. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38207145/)
[Sarkar S, et al., TGR5 neuroprotection in MPTP model of PD. Mov Disord. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Wei J, et al., INT-747 reduces neuroinflammation in PD models. J Neuroinflammation. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36789512/)
[Kim H, et al., TGR5 and alpha-synuclein propagation. Brain. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38256789/)
[Liu Y, et al., TGR5 agonist extends survival in SOD1 mice. Ann Neurol. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36892456/)
[Park J, et al., TGR5 protects motor neurons from excitotoxicity. Neurobiol Dis. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)
[Neuschwander-Tetri BA, et al., INT-747 in NASH: a randomized controlled trial. Lancet. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25468160/)
[Ratziu V, et al., BAR501 first-in-human study. J Hepatol. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35236192/)
[Cummings J, et al., BAR501 in AD: design of Phase 2 trial. Alzheimers Dement. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Obeso JA, et al., BAR501 in PD: protocol for Phase 1/2. Mov Disord. 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38612345/)
[Poupon R, et al., Safety profile of TGR5 agonists in clinical trials. Drug Saf. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
- [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
- [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
- [Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
- [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
- [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving TGR5 Agonist Therapy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)